Keyphrases
Best Response
16%
Cytotoxic Chemotherapy
16%
Diarrhea
16%
Disease Control
16%
Disease Control Rate
16%
Disease Progression
16%
ECOG Performance Status
16%
Expanded Access
16%
First-line Therapy
100%
Gefitinib
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Median Overall Survival
16%
Metastatic Non-small Cell Lung Cancer
33%
No Evidence of Disease
16%
Overall Response Rate
16%
Partial Response
16%
Platinum-based Chemotherapy
16%
Poor Performance Status
16%
Previously Untreated
16%
Previously Untreated Patients
16%
Progression-free Survival
16%
Progressive Disease
16%
Rash
16%
Stable Disease
16%
Treatment Toxicity
16%
University Experience
100%
University of Washington
100%
Medicine and Dentistry
Compassionate Use
16%
Cytotoxic Chemotherapy
16%
Diarrhea
16%
Disease Exacerbation
16%
Diseases
50%
Electrocorticography
16%
Exanthem
16%
Gefitinib
100%
Non Small Cell Lung Cancer
100%
Overall Survival
16%
Progression Free Survival
16%
Progressive Disease
16%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
16%
Cytotoxic Chemotherapy
16%
Diarrhea
16%
Disease Exacerbation
16%
Diseases
66%
Gefitinib
100%
Non Small Cell Lung Cancer
100%
Overall Survival
16%
Progression Free Survival
16%
Rash
16%